Update on open label phase II study of IMM-101 in advanced melanoma

Following the completion of study IMM‑101‑001, patients were given the option of enrolling in a long-term follow-up study (IMM‑101‑008) and ten did so: five-year survival data from the study were presented at the ESMO Immuno-oncology Conference in Lausanne in November 2015. Although these data are uncontrolled and should thus be considered anecdotal in terms of their indications of clinical activity, it was notable that six patients were still receiving IMM‑101 after five years of treatment (a 5 year survival rate of 33%). The updated survival results from the extended Phase I study are shown in the figure below and are currently being prepared for full publication.

Six-year survival data are being reported currently and show that as of December 2016, 5 patients are still receiving IMM‑101 after 6 years of treatment and 1 patient has withdrawn from the study.